Abbott Laboratories faces scrutiny over profitability and valuation following its full-year 2025 financial results.

Analysis highlighted a compressed net profit margin compared to the previous year.

Fourth-quarter revenue reached $11.5 billion. Basic EPS was $1.02.

Earnings are projected to grow. Pressure on recent profitability metrics remains a key discussion point for investors.

The report questions the current stock valuation. Abbott's share price exceeds its discounted cash flow (DCF) fair value.

This valuation concern, combined with margin pressures, challenges the narrative of Abbott as a steady compounder.